An observational study in SARS-CoV-2, sponsored by Instituto de Investigación Marqués de Valdecilla. Status unknown at 1 site in Spain. Open to participants aged 1 Year to 100 Years. Per ClinicalTrials.gov, last updated 2021-09-16.
Sponsored by Instituto de Investigación Marqués de Valdecilla · Observational
The infection caused by COVID19 worldwide makes it necessary to monitor drugs administered for the treatment of patients hospitalized with SARS-CoV-2. In order to know more about the efficacy and safety of the treatments used, researchers from the Cantabrian health service have developed an observational study, in the form of an ambispective registry, in which clinical data from patients treated with the different drugs currently recommended by the Spanish Agency of Medicines and Health Products (SAMHP) and the Ministry of Health, or others that may arise, are collected and analyzed.
Although the conduct of clinical trials is a priority at this time, we cannot lose the clinical experience that is currently being generated, which may allow us to improve the therapeutic strategies for future patients.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →Instituto de Investigación Marqués de Valdecilla is the lead sponsor of 32 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The subject of the study is any person diagnosed with COVID-19 who is admitted to a hospital either as an inpatient or in an intensive care unit (ICU).
Exclusion Criteria:
Drug: Patients with the treatment agains COVID19
Data will be collected from patients who receive any of the treatments included in the "Technical Document. Manejo clínico del COVID-19: tratamiento médico" of the Ministry of Health, and "Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2" of the AEMPS, either as antivirals or as treatment of the inflammatory process in patients with SARS, or others as they arise.
Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice
Measured in terms of clinical recovery
Time frame: 6 months
Risk factors or modifiers of pharmacological effect such as demographic characteristics, comorbidity or underlying pathology, concomitant medication.
Time frame: 6 months
Information on the patterns of use of these drugs (dose, duration of treatment,
to know the use according to the Ministry of Health Technical Document
Time frame: 6 months
Adverse events
Adverse effects of the medicines used
Time frame: 6 months
Time of hospital admission and/or stay in ICU and maximum severity reached.
Time frame: 6 months
Treatments for SARS-CoV-2 positive patients not described in the protocol
Determine the evolution of the treatments
Time frame: 6 months
healthy survey for patients after their recovery/discharge from hospital.
It is composed of 10 items, with scores from 0 (worst health) to 100 points (best health)
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto de Investigación Marqués de Valdecilla